• PMH41 - COST-UTILITY ANALYSES OF INFORMAL CAREGIVER INTERVENTIONS- A CRITICAL REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPM

    Oct 1, 2018, 00:00

  • PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE

    Oct 1, 2018, 00:00

  • PND3 - SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS IN PAEDIATRIC PATIENTS WITH FOCAL SEIZURES – ARE CURRENTLY APPROVED THERAPIES SUFFICIENT FOR THE MANAGEMENT OF PAEDIATRIC PATIENTS?

    Oct 1, 2018, 00:00

  • PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMEN

    Oct 1, 2018, 00:00

  • PRS66 - ANALYSIS OF INDICATORS OF AVAILABILITY AND CONSUMPTION ANTIHISTAMIN PREPARATIONS IN UKRAINE IN 2017

    Oct 1, 2018, 00:00

  • PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINA

    Oct 1, 2018, 00:00

  • PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS- AN ONTARIO, CANADA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN’S LYMPHOMA

    Oct 1, 2018, 00:00

  • PRM261 - INCORPORATION OF OBSERVATIONAL DATA INTO NETWORK META-ANALYSIS- A CASE STUDY

    Oct 1, 2018, 00:00

  • CV4 - PATIENT AND CAREGIVER INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMD64 - THE ROLE OF INFORMATION PROVISION IN ECONOMIC EVALUATIONS OF NON-INVASIVE PRENATAL TESTING- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PRM163 - AN APPROACH TO EVALUATING THE EFFECT OF PRIORS IN NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PND113 - HEALTH TECHNOLOGY ASSESSMENT OF MRGFUS FOR THE TREATMENT OF ESSENTIAL TREMOR IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PSS46 - DIFFERENCES IN HTA COVERAGE RECOMMENDATIONS- COMPARING OPHTHALMOLOGY DRUG REIMBURSEMENT DECISIONS IN FOUR EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCP21 - BIOSIMILARS IN THE UK – A 2018 UPDATE

    Oct 1, 2018, 00:00

  • PCV161 - FOCUS ON LIFE QUALITY IN RECONSTRUCTION VASCULAR SURGERY

    Oct 1, 2018, 00:00

  • PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESS

    Oct 1, 2018, 00:00

  • PRS68 - HEALTH RESOURCE UTILIZATION (HRU) AMONG INFANTS DIAGNOSED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE NETHERLANDS- A RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

    Oct 1, 2018, 00:00

  • PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PRM195 - THE INFANT GASTROESOPHAGEAL REFLEX DISEASE QUESTIONNAIRE (I-GERQ-R)- A META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PRM99 - TRENDS IN OPIOID PRESCRIBING IN PRIMARY CARE PHYSICIAN OFFICES IN THE UNITED STATES- 2006-2015

    Oct 1, 2018, 00:00

  • PRM79 - WEBER EFFECT- AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

    Oct 1, 2018, 00:00

  • PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIA

    Oct 1, 2018, 00:00

  • PMD89 - COST-EFFECTIVENESS OF OXIGEN THERAPY WITH C-PAP FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA) VERSUS THE STANDARD OF CARE IN THE MEXICAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2018, 00:00

  • PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTING

    Oct 1, 2018, 00:00

  • PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMS66 - IMPROVING PATIENT AND FINANCIAL OUTCOMES IN THE NHS- EARLY ARTHRITIS SERVICE INCREASES PATIENT SATISFACTION WHILST SAVING COSTS

    Oct 1, 2018, 00:00

  • PSY18 - RAPID IMPROVEMENTS IN MOTOR FUNCTION IN SPINAL MUSCULAR ATROPHY TYPE 1 FOLLOWING AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PHP328 - REAL-WORLD-DATA AND REAL-WORLD-EVIDENCE STATE OF ART FROM A LITERATURE REVIEW PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP349 - THE EVOLUTION OF STANDARD MONITORING REGISTRIES IN THE ITALIAN MARKET

    Oct 1, 2018, 00:00

  • PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS

    Oct 1, 2018, 00:00

  • PND150 - IMPACT OF INOTERSEN ON CONDITION-SPECIFIC QUALITY OF LIFE (QOL) FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIA

    Oct 1, 2018, 00:00

  • PIH22 - ECONOMIC IMPACT OF DONOR HUMAN MILK VERSUS FORMULA FOR VERY LOW BIRTH WEIGHT INFANTS IN THE NEONATAL INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PSY125 - PHYSICIANS' AND PHARMACISTS’ PRIORITIES IN TREATMENT DECISION-MAKING FOR CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2018, 00:00

  • PMD86 - POTENTIAL COST-EFFECTIVENESS OF SPECTRAL PHOTON-COUNTING COMPUTED TOMOGRAPHY (SPCCT) VERSUS CT COMBINED TO CT ANGIOGRAPHY (CTA) IN THE IDENTIFICATION AND TREATMENT OF ISCHAEMIC STROKE PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PSY11 - REAL-WORLD EXPERIENCE OF GENERALIZED LIPODYSTROPHY PATIENTS ENROLLED IN THE METRELEPTIN EARLY ACCESS PROGRAM- INITIAL RESULTS

    Oct 1, 2018, 00:00

  • PRM173 - DISCRIMINATIVE VALIDITY OF THE EQ-5D-5L AND SF-12 IN OLDER ADULTS WITH ARTHRITIS

    Oct 1, 2018, 00:00

  • PSY86 - HIGHER LEVELS OF SKIN CLEARANCE ARE ASSOCIATED WITH DECREASED INDIRECT COSTS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC)- RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

    Oct 1, 2018, 00:00

  • PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS101 - IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON QUALITY OF LIFE- FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB98 - TYPE 2 DIABETES- REAL-LIFE STUDY BASED ON SNIIRAM DATA OF PATIENTS INITIATING AGLP1 IN 2016

    Oct 1, 2018, 00:00

  • PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAIN

    Oct 1, 2018, 00:00

  • PHP54 - DIRECTIVE 2004/18/EC- IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE

    Oct 1, 2018, 00:00

  • PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINA

    Oct 1, 2018, 00:00

  • PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIES

    Oct 1, 2018, 00:00

  • PCP17 - IMPACT OF THE ICER VALUE ASSESSMENT FRAMEWORK ON DRUG PRICING IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTS

    Oct 1, 2018, 00:00

  • PRM105 - REAL WORLD EVIDENCE- DOES THE POPULARITY OF THE TERM REFLECT IN PUBLICATION NUMBERS?

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PRS26 - THE ECONOMIC BURDEN OF ASTHMA IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS

    Oct 1, 2018, 00:00

  • PHP228 - THE IMPACT OF LABEL EXTENSIONS ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ASSESSED ACCORDING TO §35A SGB V IN GERMANY - ONCOLOGICAL AND METABOLIC DISEASES

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN

    Oct 1, 2018, 00:00

  • PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PRM245 - EXTRAPOLATION OF SURVIVAL IN THE CONTEXT OF ECONOMIC MODELLING USING BAYESIAN MODEL AVERAGING- AN APPLICATION IN RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE- A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY

    Oct 1, 2018, 00:00

  • PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017

    Oct 1, 2018, 00:00

  • PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE

    Oct 1, 2018, 00:00

  • CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PMU37 - INTRODUCTION RATE OF NEW HEMATO-ONCOLOGY DRUGS IN CATALONIA

    Oct 1, 2018, 00:00

  • PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMS113 - TOWARD PATIENT-CENTERED VALUE ASSESSMENT- LESSONS FROM THE IVI OPEN-SOURCE VALUE PROJECT

    Oct 1, 2018, 00:00

  • PND38 - ECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN PATIENTS WITH LOW PHYSICAL DISABILITY

    Oct 1, 2018, 00:00

  • PRS51 - COMPARISON OF THE TREATMENT OPTIONS FOR COW'S MILK PROTEIN ALLERGY- A COST MINIMIZATION ANALYSIS BASED ON REAL WORLD CONDITIONS OF TURKEY

    Oct 1, 2018, 00:00

  • PUK17 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PMH67 - COMPLIANCE WITH ANTIDEPRESSANT MEDICATION IN KOREA- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PMD132 - REAL-WORLD ECONOMIC AND CLINICAL OUTCOMES FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING RADIOFREQUENCY ABLATION USING THERMOCOOL® SF CATHETER VERSUS THERMOCOOL® CATHETER

    Oct 1, 2018, 00:00

  • PND104 - RECOMMENDATIONS FOR A NATIONAL MULTIPLE SCLEROSIS (MS) STRATEGY

    Oct 1, 2018, 00:00

  • PRM228 - EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION- IMPLEMENTATION OF GUYOT’S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMS34 - THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN- RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS)

    Oct 1, 2018, 00:00

  • PRS31 - THE ECONOMIC IMPACT OF OPTIMIZED POST-HOSPITALIZATION MANAGEMENT FOR AN EXACERBATION IN COPD PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PND58 - COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

    Oct 1, 2018, 00:00

  • PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS- THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTS

    Oct 1, 2018, 00:00

  • PMD45 - BIOMARKER-GUIDED RISK ASSESSMENT OF ACUTE KIDNEY INJURY- RESULTS OF A COSTING MODEL FROM A UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKE

    Oct 1, 2018, 00:00

  • PRM260 - GENERATION OF RECONSTRUCTED INDIVIDUAL PATIENT DATA FROM DIGITIZED CURVES IN COST-EFFECTIVENESS MODEL- A DISCRETE OPTIMIZATION APPROACH

    Oct 1, 2018, 00:00

  • PMS111 - PATIENTS’ PREFERENCES FOR TREATMENT OF PSORIATIC ARTHRITIS BASED ON A DISCRETE CHOICE EXPERIMENT. RESULTS OF THE COEPSO STUDY

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLAND

    Oct 1, 2018, 00:00

  • PMD17 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN BARBED AND CONVENTIONAL SUTURES AMONG PATIENTS UNDERGOING SPINE SURGERY

    Oct 1, 2018, 00:00

  • PIN86 - COST SAVINGS TO BE EXPECTED FROM THE INTRODUCTION OF NEW ANTI-HIV GENERICS IN UNIVERSITY PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PSY113 - ASSESSMENT OF BASIC HEALTH TECHNOLOGIES FOR ACROMEGALY PHARMACOTHERAPY IN UKRAINE

    Oct 1, 2018, 00:00

  • PRM269 - SYSTEMATIC LITERATURE REVIEW (SLR) EVALUATING QUALITY ASSESSMENT TOOLS (QAT)

    Oct 1, 2018, 00:00

  • PMH50 - TREATMENT OF OPIOID USE DISORDER IN ITALY- IS THERE SCOPE FOR POLICY CHANGE?

    Oct 1, 2018, 00:00

  • PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PCN292 - CANCER DRUGS IN GERMANY- HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PSY204 - EARLY ENGAGEMENT OF THE “PATIENT VOICE” TO INFORM PATIENT REPORTED OUTCOME (PRO) MEASUREMENT IN GLOBAL PIVOTAL TREATMENT TRIAL OF CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PRM141 - COMPARISON OF NOVEL BAYESIAN METHODS USING EXTERNAL DATA TO IMPROVE SURVIVAL ESTIMATIONS FROM IMMATURE SURVIVAL DATA

    Oct 1, 2018, 00:00

  • PMD12 - AMBULATORY BLOOD PRESSURE MONITORING IN THE DIAGNOSIS AND MANAGEMENT OF ARTERIAL HYPERTENSION IN CURRENT MEDICAL PRACTICE IN ALGERIA- MAPA DZ STUDY - INTERIM ANALYSIS

    Oct 1, 2018, 00:00

  • PRS77 - SOCIOECONOMIC DETERMINANTS OF SMOKING IN GREECE

    Oct 1, 2018, 00:00

  • PCN215 - EMERGING TRENDS IN THE MANAGEMENT OF NSCLC PD-L1+ PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PDB115 - IS USING MMAS-8 ALONE RELIABLE AND NONBIAS WHEN MEASURING MEDICATION ADHERENCE?

    Oct 1, 2018, 00:00

  • PRM22 - SERVICE IMPACT MODELLING AS A TOOL TO SUPPORT MARKET ACCESS FOR HEALTH TECHNOLOGY INNOVATION

    Oct 1, 2018, 00:00

  • PMD151 - SURGICAL TREATMENT, COMPLICATIONS, HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ACROMIOCLAVICULAR DISLOCATIONS

    Oct 1, 2018, 00:00

  • PDB92 - PHYSICIANS’ ADHERENCE TO CLINICAL PRACTICE GUIDELINES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS. THE IMPLICA2 STUDY

    Oct 1, 2018, 00:00

  • PRS34 - COST AND DRUG UTILIZATION TRENDS IN INHALED CORTICOSTEROIDS/LONG-ACTING BETA AGONISTS (ICS/LABA) FIXED-DOSE COMBINATIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN242 - HOW FAR DOES HIGH EXPENDITURE IMPLY EFFECTIVENESS? A STUDY OF THE RELATION BETWEEN ONCOLOGICAL DRUG EXPENDITURE AND HEALTH OUTCOMES FROM 37 COUNTRIES

    Oct 1, 2018, 00:00

  • PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS

    Oct 1, 2018, 00:00

  • PND14 - LONG-TERM EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ANTIDEMENTIA THERAPIES IN MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PND5 - A LITERATURE REVIEW REPORTING THE SIDE EFFECTS AND ANY RELATED CONSEQUENCES CAUSED BY CURRENT CHRONIC MYASTHENIA GRAVIS TREATMENTS

    Oct 1, 2018, 00:00

  • PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PND126 - SYSTEMATIC REVIEW OF THE BURDEN OF PEDIATRIC MULTIPLE SCLEROSIS IN NORTH AMERICA AND EUROPE

    Oct 1, 2018, 00:00

  • PSS44 - AN EVALUATION OF THE CURRENT TREATMENT PATHWAYS AND ASSOCIATED NHS RESOURCE USE FOR THE MANAGEMENT OF UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS IN SECONDARY CARE

    Oct 1, 2018, 00:00

  • PCV55 - ECONOMIC BURDEN OF STROKE IN GERMANY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMS1 - COMPARATIVE EFFECTIVENESS OF BARICITINIB VERSUS SARILUMAB IN RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENT

    Oct 1, 2018, 00:00

  • PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PCN319 - RCT NOT RWE- TWO YEAR REPORT CARD FOR THE CANCER DRUGS FUND REFORMS

    Oct 1, 2018, 00:00

  • PMS108 - HIGH-FREQUENCY ULTRASOUND EXAMINATION OF LATERAL ANKLE LIGAMENT INJURIES IN CHILDREN

    Oct 1, 2018, 00:00

  • PRM182 - CULTURAL ADAPTATION AND LOCALISATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) INTO ARABIC VARIANTS TO ENSURE CULTURAL SUITABILITY.

    Oct 1, 2018, 00:00

  • PND95 - THE ECONOMIC BURDEN OF NERVE RELATED INJURIES IN SPINAL CLAIMS IN THE UK

    Oct 1, 2018, 00:00

  • PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMH62 - DEPRESCRIBING OF BENZODIAZEPINES AMONGST THE PATIENTS OF DEPARTMENT OF PSYCHIATRY IN A TERTIARY CARE HOSPITAL, BANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PSS70 - ACNE AND ABSENTEEISM- RESULTS OF A REAL-LIFE STUDY

    Oct 1, 2018, 00:00

  • PHP279 - ASSESSMENT OF THE NICE FAST-TRACK APPRAISAL (FTA) PROCESS

    Oct 1, 2018, 00:00

  • PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO- WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?

    Oct 1, 2018, 00:00

  • PRM237 - PERFORMANCE OF PROPENSITY SCORE MATCHING IN SMALL SAMPLES - SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PRM222 - STUDY OF THE SEVERITY OF VASO-OCCLUSIVE CRISIS FOR PATIENT SUFFERING FROM SICKLE CELL DISEASE IN FRANCE USING A MACHINE LEARNING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PRM60 - THE BURDEN OF OSTEOPOROSIS IN FOUR LATIN AMERICAN COUNTRIES- BRAZIL, MEXICO, COLOMBIA, AND ARGENTINA.

    Oct 1, 2018, 00:00

  • PRM272 - THE EUNETHTA TRANSFERABILITY TOOL- APPLICATION TO NOVEL TREATMENTS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE IRISH HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PUK37 - USE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) INSTRUMENTS IN CLINICAL TRIALS OF ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD)

    Oct 1, 2018, 00:00

  • PCN317 - THE CANCER DRUGS FUND- KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET

    Oct 1, 2018, 00:00

  • PND88 - DESCRIBING REAL WORLD TREATMENT PATTERNS IN PAEDIATRIC DRAVET SYNDROME PATIENTS IN DENMARK USING ELECTRONIC MEDICAL RECORDS

    Oct 1, 2018, 00:00

  • PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV46 - PHARMACOECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF IVABRADINE IN CHINA

    Oct 1, 2018, 00:00

  • PMD165 - EVALUATING DIGITAL HEALTH TECHNOLOGIES- A REVIEW OF HTA GUIDANCE AND ASSESSMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMS92 - THE CORRELATION BETWEEN MENTAL DISORDER PARAMETERS AND MEDICAL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017

    Oct 1, 2018, 00:00

  • PSY197 - LIMITATIONS OF THE EQ5D INSTRUMENT IN THE ASSESSMENT OF QUALITY OF LIFE IN CHRONIC RARE DISEASES – A CASE STUDY FROM FCS

    Oct 1, 2018, 00:00

  • PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.

    Oct 1, 2018, 00:00

  • PSY170 - IMPACT OF MULTIPLE INDICATIONS ON PRICE AND ACCESS OF DRUGS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PMS21 - BUDGET IMPACT MODEL OF INCLUSION OF TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Oct 1, 2018, 00:00

  • PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OS

    Oct 1, 2018, 00:00

  • PRS71 - WASTEFUL HEALTHCARE SPENDING ON MEDICATION OVERSUPPLY IN ROUTINE USES OF COMBINED INHALED CORTICOSTEROID AND LONG-ACTING BETA2-AGONISTS (ICS/LABA) INHALERS

    Oct 1, 2018, 00:00

  • PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS PROPHYLAXIS USE OF EMICIZUMAB IN HIGH TITER INHIBITORY HEMOPHILIA A PATIENTS IN IRAN; A COST UTILITY ANALYSIS

    Oct 1, 2018, 00:00

  • ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON’S DISEASE

    Oct 1, 2018, 00:00

  • PUK22 - ESTIMATES OF KIDNEY STONES COSTS. AN ANALYSIS OF CLINICAL AND ADMINISTRATIVE DATA TO MEASURE THE BURDEN OF KIDNEY STONES IN ITALY

    Oct 1, 2018, 00:00

  • PMD164 - THE MANAGEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS (T2)- THE ROLE OF GLYCATED ALBUMIN

    Oct 1, 2018, 00:00

  • PCN157 - COST-EFFECTIVENESS ANALYSIS OF THE USE OF COLONOSCOPY AS A SCREENING METHOD FOR COLON CANCER IN PATIENTS OVER 50 YEARS OF AGE ON MANDATORY HEALTH INSURANCE

    Oct 1, 2018, 00:00

  • PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PMS120 - THE IMPACT OF RHEUMATOID ARTHRITIS (RA) ON A PATIENT’S ABILITY TO WORK AND EARLY RETIREMENT DUE TO RA

    Oct 1, 2018, 00:00

  • PMU102 - A MULTIVARIATE APPROACH THAT ALLOWS COMPREHENSIVE SCORING OF MULTI-FACETED CONCEPTS- FOCUS ON MEDICINE ACCEPTABILITY IN VULNERABLE POPULATIONS

    Oct 1, 2018, 00:00

  • PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PMD3 - METHODS FOR QUANTIFYING POSTERIOR CAPSULAR OPACIFICATION AND THE IMPACT OF INTRAOCULAR LENS MATERIAL ON SEVERITY SCORES - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU14 - COMPARISON TO STANDARD OF CARE- MODELISATION OF POTENTIAL SELECTION BIAS FOR ACTIVE REFERENCE IN RANDOMISED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5

    Oct 1, 2018, 00:00

  • PND26 - COST IMPLICATIONS OF A NOVEL WEIGHT DOSED TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRM167 - MAPPING THE SF-36 TO EQ-5D-3L IN RANDOMIZED TRIAL- THE EMOCAR STUDY (MAY 2011 – APRIL 2016)

    Oct 1, 2018, 00:00

  • PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES- A COMPARISON IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITY

    Oct 1, 2018, 00:00

  • PMD123 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN ELECTIVE HIP AND KNEE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCP69 - APPLICATION DECREE OF JARDE LAW- EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PRM27 - PREDICTING STABILITY OUTCOMES FOR FOSTERED CHILDREN USING MACHINE LEARNING- APPLICATION OF OUTCOME RESEARCH TO SOCIAL CARE

    Oct 1, 2018, 00:00

  • PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY- A LANDSCAPE ANALYSIS

    Oct 1, 2018, 00:00

  • PIN46 - COST-EFFECTIVENESS COMPARISON OF BALOXAVIR MARBOXIL AND LANINAMIVIR FOR THE TREATMENT OF INFLUENZA IN JAPAN

    Oct 1, 2018, 00:00

  • PSY183 - SCOPE REVIEW OF ORPHAN DRUG PUBLIC POLICIES AND LEGISLATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PRS37 - ECONOMIC BURDEN ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU69 - DESCRIPTION OF HEALTH CARE ACTIVITY OF A NUTRITION AREA MANAGED BY A HOSPITAL PHARMACY SERVICE

    Oct 1, 2018, 00:00

  • HT1 - CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PDB83 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN NON-INSULIN ANTIDIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016

    Oct 1, 2018, 00:00

  • PND48 - HEALTH AND ECONOMIC BURDEN OF PARKINSON’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...

    Oct 1, 2018, 00:00

  • PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PRM82 - REAL WORLD EVIDENCE (RWE) FROM ITALIAN NHS-AIFA REGISTRIES

    Oct 1, 2018, 00:00

  • PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PHP128 - 3F - FORMULA FOR FUNDING- RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEM

    Oct 1, 2018, 00:00

  • PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCE

    Oct 1, 2018, 00:00

  • PCV61 - PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAIN

    Oct 1, 2018, 00:00

  • PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA

    Oct 1, 2018, 00:00

  • PRS11 - INITIATION OF TRIPLE THERAPY IN NEWLY DIAGNOSED COPD PATIENTS

    Oct 1, 2018, 00:00

  • PMU39 - PRICE ASSESSMENT OF ESSENTIAL GENERICS IN THE CITY OF YEREVAN

    Oct 1, 2018, 00:00

  • PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN)- A DISCRETE EVENT PATIENT SIMULATION

    Oct 1, 2018, 00:00

  • PSY167 - COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES (DRDS) EVALUATED BY CADTH AND NICE.

    Oct 1, 2018, 00:00

  • PRS82 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS- A DECADE EXPERIENCE OF A NATIONAL HEALTH INSURANCE PROGRAM

    Oct 1, 2018, 00:00

  • MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL- A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICES

    Oct 1, 2018, 00:00

  • PMU62 - ECONOMIC EVALUATION OF MESALAZINE 4G (SALOFALK®) IN THE TREATMENT OF PATIENTS WITH ULCERATIVE COLITIS LOCATED IN THE RECTUM AND SIGMOID

    Oct 1, 2018, 00:00

  • PSY2 - IDENTIFICATION OF POTENTIAL BIAS FROM DATA SOURCES AND STUDY DESIGNS USED TO ESTIMATE PLATELET TRANSFUSION ADVERSE EVENT RATES

    Oct 1, 2018, 00:00

  • PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHM

    Oct 1, 2018, 00:00

  • PRS76 - DISEASE ADAPTATION AND PERCEIVED HEALTH STATUS- DOES IT EXIST AND CAN IT BE QUANTIFIED? INVESTIGATING EQ-5D IN SEVERE ASTHMA

    Oct 1, 2018, 00:00

  • PHP221 - CONDITIONAL APPROVAL- ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?

    Oct 1, 2018, 00:00

  • PIN113 - ASSESSMENT OF THE EFFICACY AND SAFETY OF ANIDULAFUNGIN, COMPARED WITH OTHER AVAILABLE ANTIFUNGALTHERAPIES TO TREAT INVASIVE CANDIDIASIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEY

    Oct 1, 2018, 00:00

  • PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PIN54 - COST-EFFECTIVENESS OF INTRODUCING MEN VACCINATION AGAINST HUMAN PAPILLOMAVIRUS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP210 - DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING

    Oct 1, 2018, 00:00

  • PRM93 - SNDS, THE FRENCH NATIONWIDE CLAIMS DATABASE- A POWERFUL TOOL FOR PHARMACOECONOMY AND PHARMACOEPIDEMIOLOGY

    Oct 1, 2018, 00:00

  • PMU24 - WHICH MODEL(S) ARE USED TO ASSESS INDIVIDUAL-LEVEL SURROGACY IN ONCOLOGY USING KENDALL’S TAU? A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PIH32 - INNOVATIVE PAYMENT MECHANISM- SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.

    Oct 1, 2018, 00:00

  • PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS

    Oct 1, 2018, 00:00

  • PRM181 - USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE FOR A SYSTEMATIC LITERATURE REVIEW OF UTILITIES IN INFECTIOUS DISEASE

    Oct 1, 2018, 00:00

  • PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT- A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

    Oct 1, 2018, 00:00

  • PDB28 - TYPE 2 DIABETES- CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY

    Oct 1, 2018, 00:00

  • PSY166 - MARKET ACCESS TRENDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE

    Oct 1, 2018, 00:00

  • PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PND123 - PATIENT AND CAREGIVER WEB-BASED SURVEY- HEALTH UTILITIES IN TUBEROUS SCLEROSIS COMPLEX (TSC) PATIENT POPULATION

    Oct 1, 2018, 00:00

  • PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS’ PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIES

    Oct 1, 2018, 00:00

  • PIN107 - BACTERIAL SKIN AND SOFT TISSUE INFECTIONS- GLOBAL MAPPING BY GEOGRAPHICAL DISTRIBUTION AND CLIMATE AREA

    Oct 1, 2018, 00:00

  • PMU46 - IN-HOSPITAL ECONOMIC BURDEN OF ANASTOMOTIC LEAKAGE AFTER COLORECTAL ANASTOMOSIS SURGERY- A REAL-WORLD COST ANALYSIS

    Oct 1, 2018, 00:00

  • PMS73 - BRIGHT FUTURE FOR THE USE OF BIOSIMILAR INFLIXIMAB- EVIDENCE-BASED ANALYSIS USING HEALTHCARE CLAIM DATABASE

    Oct 1, 2018, 00:00

  • PHP294 - A REVIEW OF RECENT APPRAISALS FROM THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW- HOW IMPORTANT IS THE ICER?

    Oct 1, 2018, 00:00

  • PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE- AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINES

    Oct 1, 2018, 00:00

  • PND31 - COST ANALYSIS OF BOTULINUM TOXIN A (BOTOX® AND XEOMIN®) IN REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN

    Oct 1, 2018, 00:00

  • PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?

    Oct 1, 2018, 00:00

  • PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA

    Oct 1, 2018, 00:00

  • PMD76 - WHICH INTENSIVE CARE ANALYTICS ARE A WORTHWHILE INVESTMENT FOR DEVELOPERS? AN EARLY HEALTH TECHNOLOGY ASSESSMENT.

    Oct 1, 2018, 00:00

  • PDB131 - LATENT CLASS ANALYSIS FOR PERSONALIZED DIABETES MANAGEMENT- ONE SIZE DOES NOT FIT ALL?

    Oct 1, 2018, 00:00

  • PSY220 - IMPACT OF KERATOCONUS AND ITS TREATMENTS ON PATIENTS’ DAILY LIFE- QUALITATIVE PHASE OF THE DEVELOPMENT OF A QUALITY OF LIFE QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PMU78 - MEDICATION THERAPY MANAGEMENT WITH DIRECT PATIENT ENGAGEMENT TO ADDRESS NON-ADHERENCE TO SPECIALTY DRUGS

    Oct 1, 2018, 00:00

  • PMD97 - TECHNOLOGICAL-ECONOMIC COMPARISON OF ENDODONTICS TECHNIQUE WITH FOCUS ON NIKL-TITAN SYSTEMS

    Oct 1, 2018, 00:00

  • PMD13 - PREVALENCE OF ISOLATED HYPERTENSION AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATION

    Oct 1, 2018, 00:00

  • PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PSY111 - PHARMACOECONOMIC EVALUATION OF BIOSIMILAR RECOMBINANT ALPHA-EPOETIN IN THE TREATMENT OF ANEMIA IN HEMODIALYSIS PATIENTS

    Oct 1, 2018, 00:00

  • PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS- A MULTINATIONAL SURVEY

    Oct 1, 2018, 00:00

  • PSS27 - A COST-EFFECTIVENESS ANALYSIS OF TWO VISUAL ACUITY CUTOFFS FOR CATARACT SURGERY IN PATIENTS WITH PSEUDOEXFOLIATION IN UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMD125 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN FRAGILITY FRACTURE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD111 - THE COST-EFFECTIVENESS OF BIMODAL AIDING COMPARED TO UNILATERAL AND BILATERAL COCHLEAR IMPLANT USE IN ADULTS WITH BILATERAL SEVERE TO PROFOUND DEAFNESS

    Oct 1, 2018, 00:00

  • PMS23 - OPTIMIZING TREATMENT FOR RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA (OPTRA)

    Oct 1, 2018, 00:00

  • PRS15 - A 10-YEAR FOLLOW-UP OF A COHORT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THROUGH A ONE-WAY MARKOV MODEL

    Oct 1, 2018, 00:00

  • PIN123 - USING EQ-5D TO MEASURE QUALITY OF LIFE IN PATIENTS WITH DIABETIC FOOT ULCERS AND VENOUS LEG ULCERS

    Oct 1, 2018, 00:00

  • PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP298 - ON THE RIGHT TRACK? EXAMINING NICE’S FAST-TRACK APPRAISAL PROCESS

    Oct 1, 2018, 00:00

  • PHP155 - THE DEVELOPMENT AND EMPIRICAL APPLICATION OF A MULTIPLE SOCIETAL VALUE CRITERIA APPROACH TO RESOURCE ALLOCATION AMONG DISEASE CATEGORIES

    Oct 1, 2018, 00:00

  • PIN77 - DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5

    Oct 1, 2018, 00:00

  • PSY82 - ANNUAL COST OF CLOTTING FACTORS IN PATIENTS WITH SEVERE (SEV) HEMOPHILIA A (HA) IN FRANCE

    Oct 1, 2018, 00:00

  • PMS41 - COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PRM69 - AN INCREASE OVER TIME IN PUBLISHED REAL-WORLD AND HEALTH ECONOMIC EVIDENCE IN CLINICAL JOURNALS ACROSS LYSOSOMAL STORAGE DISORDERS

    Oct 1, 2018, 00:00

  • PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSION

    Oct 1, 2018, 00:00

  • PCP26 - THE EUNETHTA COMPANION GUIDE – A REPOSITORY TO STRENGTHEN THE QUALITY OF EUNETHTA’S JOINT HTA PRODUCTION

    Oct 1, 2018, 00:00

  • Association between Higher Generic Drug Use and Medicare Part D Star Ratings- An Observational Analysis

    Oct 1, 2018, 00:00

  • PMU28 - A CROSS INDICATION BUDGET IMPACT ANALYSIS OF SECUKINUMAB- A GREEK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD- INITIAL ESTIMATES IN REPUBLIC OF BELARUS

    Oct 1, 2018, 00:00

  • PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PND135 - FATIGUE IN MULTIPLE SCLEROSIS- ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE MFIS-5 QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PSY122 - MANAGEMENT OF POOR PROGNOSIS MULTIPLE MYELOMA PATIENTS UNDER REGULAR CLINICAL CONDITIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PMS28 - SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PMU118 - COGNITIVE DEBRIEFING INTERVIEW STUDIES TO INFORM PATIENT-REPORTED OUTCOME QUESTIONNAIRE DEVELOPMENT- A LITERATURE REVIEW AND SUGGESTED REPORTING GUIDELINES

    Oct 1, 2018, 00:00

  • PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIR

    Oct 1, 2018, 00:00

  • PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASES

    Oct 1, 2018, 00:00

  • PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Oct 1, 2018, 00:00

  • HT2 - PATIENT CENTRIC MEASURES IN HTAS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PCN355 - UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS- KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PMH75 - PATIENT-REPORTED OUTCOMES IN PATIENTS WITH DEPRESSION- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PGI6 - 30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION

    Oct 1, 2018, 00:00

  • PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTS

    Oct 1, 2018, 00:00

  • PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONS

    Oct 1, 2018, 00:00

  • PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMD133 - SUCCESS FACTORS FOR §137H SGB V ASSESSMENT OF MEDICAL DEVICES IN GERMANY

    Oct 1, 2018, 00:00

  • PSS24 - ESTIMATION OF THE LONG-TERM POPULATION COSTS AND BENEFITS FOR FIVE DIFFERENT VARICELLA CHILDHOOD IMMUNIZATION STRATEGIES IN BULGARIA

    Oct 1, 2018, 00:00

  • PUK25 - EVALUATION OF THE RECOMMENDATIONS COMPLIANCE ON THE DIABETIC NEPHROPATHY MANAGEMENT IN FRANCE- THE ND-CRIS COHORT (2012-2017)

    Oct 1, 2018, 00:00

  • PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING- IMPLICATIONS FOR RECRUITMENT

    Oct 1, 2018, 00:00

  • PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PSY120 - ECONOMIC BURDEN OF SYMPTOMATIC MULTIPLE MYELOMA ON THE ITALIAN HEALTH CARE SYSTEM- FOCUS ON THE MAIN DRIVER COSTS.

    Oct 1, 2018, 00:00

  • PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)

    Oct 1, 2018, 00:00

  • PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE- A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMH19 - BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALY

    Oct 1, 2018, 00:00

  • PRM103 - SECONDARY USE OF EXISTING PERSONAL HEALTH DATA FOR NON-INTERVENTIONAL STUDIES IN FRANCE

    Oct 1, 2018, 00:00

  • PRM130 - OPEN-SOURCE SOFTWARE FOR DEVELOPING COMPUTATIONALLY EFFICIENT COST-EFFECTIVENESS MODELS TO EVALUATE SEQUENTIAL TREATMENT STRATEGIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIA

    Oct 1, 2018, 00:00

  • PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?

    Oct 1, 2018, 00:00

  • PMU50 - COSTS OF NEUROMONITORING - EXAMINING THE POST-OPERATIVE FINANCIAL BURDEN TO PATIENTS FOLLOWING SPINAL SURGERY

    Oct 1, 2018, 00:00

  • PRM213 - LEARNINGS FROM CONSUMER RESEARCH FOR PATIENT PREFERENCE RESEARCH

    Oct 1, 2018, 00:00

  • PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE- RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEY

    Oct 1, 2018, 00:00

  • PMS24 - COST MINIMIZATION ANALYSIS OF THIRD LINE RHEUMATOID ARTHRITIS DRUGS IN ECUADOR

    Oct 1, 2018, 00:00

  • PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS- COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Oct 1, 2018, 00:00

  • PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE

    Oct 1, 2018, 00:00

  • PIN122 - INVESTIGATION OF FACILITATING FACTORS OF PARENTS’ DECISION-MAKING IN VACCINATION

    Oct 1, 2018, 00:00

  • PND138 - INFORMATION SEARCHING PREFERENCES IN PEOPLE WITH MULTIPLE SCLEROSIS- THE INFOSEEK STUDY

    Oct 1, 2018, 00:00

  • PHP16 - CHANGE IN THE QUANTITY OF ONE-DAY SURGERY INTERVENTIONS BETWEEN 1997-2017 IN HUNGARY

    Oct 1, 2018, 00:00

  • PRM270 - IMPACT OF THE CLINICAL TRIAL DESIGN STRATEGY ON PRODUCT MARKET UPTAKE AND OVERALL COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PCV100 - ANALYSIS OF DEMOGRAPHY DATA OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO TYPE OF INSTITUTE IN HUNGARY

    Oct 1, 2018, 00:00

  • PMD47 - BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH DIABETES MELLITUS TYPE II IN THE UNITED KINGDOM AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?

    Oct 1, 2018, 00:00

  • PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIES

    Oct 1, 2018, 00:00

  • PRM273 - METHODOLOGICAL CONSIDERATIONS ON THE RECOMMENDATIONS TO CONDUCT AND REPORT SYSTEMATIC REVIEWS IN MEDICAL LITERATURE- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BA

    Oct 1, 2018, 00:00

  • PRM238 - A SIMULATION STUDY ASSESSING THE USE OF PLAUSIBLY VAGUE PRIOR DISTRIBUTIONS IN A BAYESIAN META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECE

    Oct 1, 2018, 00:00

  • PMD62 - ADVANCEMENT IN SELF-MONITORING OF BLOOD GLUCOSE (SMBG) TECHNOLOGY IMPROVES METABOLIC CONTROL, DIABETES MANAGEMENT AND PATIENT SATISFACTION IN PATIENTS WITH DIABETES AND HAS THE POTENTIAL FOR SUBSTANTIAL COST SAVINGS FOR THE GERMAN H ...

    Oct 1, 2018, 00:00

  • PRS87 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUALITATIVE INTERVIEW FINDINGS

    Oct 1, 2018, 00:00

  • PSY150 - INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE

    Oct 1, 2018, 00:00

  • PHP160 - PRESCRIPTION CHARGES IN SCOTLAND- THE IMPACT OF FREE PRESCRIPTIONS

    Oct 1, 2018, 00:00

  • PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVO

    Oct 1, 2018, 00:00

  • PND130 - MEASURING WHAT MATTERS TO PEOPLE WITH MULTIPLE SCLEROSIS AND PREFERENCES FOR NOVEL METHODS TO ASSESS CLINICAL OUTCOMES

    Oct 1, 2018, 00:00

  • PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PSY41 - OVERALL SURVIVAL AND NON-RELAPSE MORTALITY OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE- VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIME

    Oct 1, 2018, 00:00

  • PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATA

    Oct 1, 2018, 00:00

  • PMD40 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING LEG ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PSY52 - ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN

    Oct 1, 2018, 00:00

  • PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMEN

    Oct 1, 2018, 00:00

  • PCN224 - TOWARDS CLINICAL ADOPTION OF REPURPOSED DRUGS IN ONCOLOGY- OVERCOMING REGULATORY AND MARKET ACCESS BARRIERS IN EUROPE

    Oct 1, 2018, 00:00

  • PMD113 - COST–UTILITY OF SURGICAL SUTURELESS BIOPROSTHESES VS. TAVI IN AORTIC VALVE REPLACEMENT FOR PATIENTS AT INTERMEDIATE AND HIGH SURGICAL RISK

    Oct 1, 2018, 00:00

  • PSY133 - LIVES SAVED FROM REDUCTIONS IN CO-PRESCRIBING OF OPIOIDS AND BENZODIAZEPINES

    Oct 1, 2018, 00:00

  • PHP46 - IS EUROPE WAKING UP TO BIOPHARMACEUTICAL INNOVATION? PERSPECTIVES FROM EXPERT APPRAISAL OF RECENT ORPHAN DISEASE THERAPY VALUE ASSESSMENTS AND THEIR SUPPORTING LEGAL / POLICY FRAMEWORKS

    Oct 1, 2018, 00:00

  • PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAIN

    Oct 1, 2018, 00:00

  • PCV54 - ESTIMATED ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN GERMANY, ITALY, AND THE UK

    Oct 1, 2018, 00:00

  • PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATION

    Oct 1, 2018, 00:00

  • PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM

    Oct 1, 2018, 00:00

  • PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATION

    Oct 1, 2018, 00:00

  • PMH8 - DEPRESSION IS ASSOCIATED WITH CHRONIC DISORDERS IN CHILDREN AND ADOLESCENTS

    Oct 1, 2018, 00:00

  • PSY48 - BUDGET IMPACT ANALYSIS OF LOW-DOSE METHOXYFLURANE FOR THE TREATMENT OF MODERATE-TO-SEVERE TRAUMA PAIN IN CONSCIOUS ADULT PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN331 - PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS

    Oct 1, 2018, 00:00

  • PSY61 - BARIATRIC SURGERY AND COSTS ASSOCIATED WITH HEALTHCARE USE AT TWO YEARS' FOLLOW-UP

    Oct 1, 2018, 00:00

  • PCN222 - TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILISATION (HCRU) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PMU47 - THE ECONOMIC BURDEN OF OCCUPATIONAL INJURY AMONG FRONTLINE CONSTRUCTION WORKERS IN GHANA

    Oct 1, 2018, 00:00

  • PIN53 - IS THE RECOMBINANT ZOSTER VACCINE ALSO COST-EFFECTIVE FOR THE GERMAN POPULATION ≥50 YEARS OF AGE?

    Oct 1, 2018, 00:00

  • PIN65 - BUDGET IMPACT ANALYSIS OF THE FIXED DOSE COMBINATION PHOSPHAZIDE/LAMIVUDINE ANTIRETROVIRAL DRUG FOR HIV TREATMENT IN RUSSA

    Oct 1, 2018, 00:00

  • PMU32 - ORPHAN DRUG PRICES IN EUROPE- IMPACT OF EXTERNAL REFERENCE PRICING

    Oct 1, 2018, 00:00

  • PCN349 - CAN WE APPLY THE UTILITY PREDICTION MATHEMATICAL MODEL FOR RECURRENT METASTATIC BREAST CANCER TO JAPANESE PATIENTS?

    Oct 1, 2018, 00:00

  • PHP194 - THE EMA CLINICAL DATA WEBSITE- A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONS

    Oct 1, 2018, 00:00

  • PCV14 - TREATMENT EFFECT OF PHARMACEUTICAL CARE FOR HYPERTENSIVE PATIENTS IN PRIMARY CARE- A SYSTEMATIC REVIEW AND META-ANALYSES

    Oct 1, 2018, 00:00

  • PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS- NOT ALWAYS A NICE OUTCOME

    Oct 1, 2018, 00:00

  • PMD112 - COST-UTILITY ANALYSIS OF VAGUS NERVE STIMULATION(VNS) FOR CHILDREN WITH INTRACTABLE EPILEPSY IN TAIWAN

    Oct 1, 2018, 00:00

  • PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PSY121 - RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES

    Oct 1, 2018, 00:00

  • PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT- A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PDB82 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM (DPP) 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER QALY CALCULATIONS MAY REVIVE ITS METFORMIN CONCLUSIONS

    Oct 1, 2018, 00:00

  • PSY222 - HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA

    Oct 1, 2018, 00:00

  • PSS54 - ETHICAL VALIDATION PROCESS FOR VIDEO RECORDED QUALITATIVE INTERVIEWS- EXPERIENCE FROM A RESEARCH PROJECT IN DERMATOLOGY IN FRANCE AND CANADA

    Oct 1, 2018, 00:00

  • PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)

    Oct 1, 2018, 00:00

  • PMU60 - IS TRANSPARENCY IN SLOVAK HTA EFFICIENT ENOUGHT? COMPARING PHARMACOECONOMICS METHODOLOGIES USED IN PRICING REIMBURSEMENT APPLICATIONS FOR INNOVATIVE THERAPIES TOWARDS REQUIREMENTS DEFINED BY THE LAW

    Oct 1, 2018, 00:00

  • PHP59 - MOVING FROM THE REGULATOR TO THE PAYER AND PRESCRIBER - HOW PHARMA CAN WORK BETTER TO EFFECTIVELY MANAGE EMERGING CHALLENGES TO THE COMMERCIAL SUCCESS OF INNOVATIVE NEW THERAPIES

    Oct 1, 2018, 00:00

  • PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US- DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEY

    Oct 1, 2018, 00:00

  • PCV22 - LIPID-LOWERING DRUG PRESCRIPTIONS IN A GROUP OF COLOMBIAN PATIENTS.

    Oct 1, 2018, 00:00

  • PSY144 - DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE UNIFIED HEALTH SYSTEM (SUS) IN SÃO PAULO - BRAZIL, IN 2017

    Oct 1, 2018, 00:00

  • PND71 - A COST MINIMISATION ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNIED KINGDOM.

    Oct 1, 2018, 00:00

  • PMS7 - LOSS OF QALYS ASSOCIATED WITH BIOSIMILAR DISCONTINUATION DUE TO NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PMU94 - DEVELOPMENT OF JAPANESE PREFERENCE WEIGHT FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT (ASCOT) SCT4

    Oct 1, 2018, 00:00

  • PSY196 - THE ECONOMIC BURDEN AND IMPACT ON QUALITY OF LIFE OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN INDIVIDUALS AGED 50 YEARS OR OLDER IN ITALY

    Oct 1, 2018, 00:00

  • PSY1 - RISK OF LIVER ENZYME ELEVATION IN AUTOIMMUNE PATIENTS WITH DIFFERENT HEPATITIS B VIRUS INFECTION STATUS RECEIVING BIOLOGIC AGENTS

    Oct 1, 2018, 00:00

  • PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PRM224 - ARE POTENTIALLY AVOIDABLE HOSPITALIZATIONS EXPLAINED BY PRIMARY CARE? BEWARE OF SPATIAL HETEROGENEITY.

    Oct 1, 2018, 00:00

  • PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALY

    Oct 1, 2018, 00:00

  • PIN125 - A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR HPV-RELATED DISEASES

    Oct 1, 2018, 00:00

  • PND45 - CAREGIVER NEED ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDY

    Oct 1, 2018, 00:00

  • PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017

    Oct 1, 2018, 00:00

  • PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN- ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVES

    Oct 1, 2018, 00:00

  • PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PSS30 - COST EFFECTIVENESS OF DIMETHYL FUMARATE (DMF) IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS- A UK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY174 - IS PHARMACOKINETIC DRIVEN THERAPY OF POTENTIAL BENEFIT IN HEMOPHILIA?

    Oct 1, 2018, 00:00

  • PSY35 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF METHYLMALONIC ACIDEMIA WITH A FOCUS ON METHYLMALONYL-COA MUTASE DEFICIENCY

    Oct 1, 2018, 00:00

  • PND78 - SOCIO-ECONOMIC IMPACT OF DRAVET SYNDROME IN GERMANY- A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PIN73 - ECONOMIC BURDEN OF HIV/AIDS AMONG ELDERLY MEDICARE BENEFICIARIES POST MEDICARE PART D

    Oct 1, 2018, 00:00

  • PSY162 - EVALUATION OF DIRECT COSTS AND TREATMENT PATTERNS ASSOCIATED WITH THE MANAGEMENT OF NEUROPATHIC PAIN IN COLOMBIA

    Oct 1, 2018, 00:00

  • PRS27 - ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS (IPF) IN CHINA

    Oct 1, 2018, 00:00

  • PMD33 - BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER (DLSR) FOR THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM8 - CLINICAL APPLICATION AND USAGE OF PATIENT REPORTED OUTCOME MEASURES IN AN ORTHOPAEDIC OUTPATIENT SETTING

    Oct 1, 2018, 00:00

  • PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINS

    Oct 1, 2018, 00:00

  • PRS7 - PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS IN KOREA - KOREAN NEONATAL NETWORK

    Oct 1, 2018, 00:00

  • PRM190 - METHODS USED TO VALUE HEALTH RELATED QUALITY IN A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN HEART FAILURE

    Oct 1, 2018, 00:00

  • PHP131 - WHAT USE IS DISTRIBUTED LEDGER TECHNOLOGY IN REAL-WORLD PRACTICE? - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PIN33 - A DYNAMIC TRANSMISSION MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

    Oct 1, 2018, 00:00

  • PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGAL

    Oct 1, 2018, 00:00

  • PRM45 - DIRECT DATA WITHOUT DUPLICATION OF EFFORT- EXPERIENCE OF OBTAINING ELECTRONIC ROUTINE RESOURCE USE DATA DIRECTLY FROM HOSPITALS FROM THE UPSTREAM RCT.

    Oct 1, 2018, 00:00

  • PCN66 - LANDMARK ANALYSES IN ONCOLOGY – SEEING BEYOND THE SURFACE AND PROPOSING A STRUCTURED DATA ANALYSIS CHECKLIST

    Oct 1, 2018, 00:00

  • PIN61 - COST-EFFECTIVENESS OF ONCE-DAILY DARUNAVIR CONTAINING SINGLE-TABLET REGIMEN (D/C/F/TAF) COMPARED WITH OTHER MULTI-TABLET REGIMENS CONTAINING BOOSTED PROTEASE INHIBITORS (BPIS)

    Oct 1, 2018, 00:00

  • PIH44 - OLDER PEOPLE WITH LONG TERM CONDITIONS USING TECHNOLOGIES SUPPORTING HOME BASED CARE- PATTERNS OF RESOURCE USE, COSTS AND HEALTH RELATED QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK- THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

    Oct 1, 2018, 00:00

  • PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS15 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PHP244 - BRIDGING THE GAP- ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMU74 - POTENTIAL COST SAVINGS BY PREVENTION OF ADVERSE DRUG EVENTS WITH A NOVEL MEDICATION REVIEW PROGRAM

    Oct 1, 2018, 00:00

  • PRS18 - POTENTIAL SAVINGS ACHIEVED THROUGH SWITCHING COPD PATIENTS FROM ICS-CONTAINING REGIMENS TO LAMA+LABA- A SPANISH PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...

    Oct 1, 2018, 00:00

  • PCP57 - LIQUID BIOPSIES IN EARLY DETECTION OF BREAST CANCER, METASTATIC PROGRESSION AND THERAPY OUTCOMES- OPPORTUNITIES AND CHALLENGES FOR THE PERSPECTIVE OF PATIENTS, PROVIDERS AND PAYERS

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63
  • 64 (current)
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • »